老虎证券

BUZZ-Soleno gains as US FDA approves its drug to treat rare genetic disorder

Reuters
03-27
BUZZ-Soleno gains as US FDA approves its drug to treat rare genetic disorder

** Shares of Soleno Therapeutics SLNO.O rise 33.98% to $65.61 premarket

** Late on Wednesday, U.S. FDA approved co's drug to treat a rare genetic disorder, making it first treatment available for patients who experience feelings of intense and persistent hunger

** The drug, to be called Vykat XR, treats hyperphagia, the hallmark symptom of the Prader-Willi syndrome, a genetic disorder that is caused by an error in one or more genes

** The drug will have an annual average cost of $466,200 and will be dosed as per patients' weight and will be available from April

** Up to last close, stock up ~9% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10